Ginkgo Bioworks Holdings Past Earnings Performance
Past criteria checks 0/6
Ginkgo Bioworks Holdings's earnings have been declining at an average annual rate of -25.3%, while the Chemicals industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 10.8% per year.
Key information
-25.3%
Earnings growth rate
-20.0%
EPS growth rate
Chemicals Industry Growth | 12.9% |
Revenue growth rate | 10.8% |
Return on equity | -86.5% |
Net Margin | -409.1% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump
Jun 18Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 11Ginkgo Bioworks: Broken Narrative
May 10Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Apr 26Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12Ginkgo Bioworks launches Ginkgo Enzyme Services
Dec 08Ginkgo, Lygos team up to produce sustainable biobased specialty chemicals
Nov 11Ginkgo, Draper develop new technologies to detect engineered DNA
Oct 17Ginkgo stock rises on acquisition of French biotech Altar
Oct 04Ginkgo Bioworks: Promising Upside But Not Without Risks
Sep 28Ginkgo Bioworks: May The Ginkgo King Grow
Sep 13Revenue & Expenses Breakdown
How Ginkgo Bioworks Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 209 | -854 | 310 | 554 |
31 Dec 23 | 251 | -893 | 351 | 581 |
30 Sep 23 | 315 | -857 | 367 | 629 |
30 Jun 23 | 326 | -1,224 | 742 | 746 |
31 Mar 23 | 390 | -1,719 | 1,080 | 892 |
31 Dec 22 | 478 | -2,105 | 1,403 | 1,053 |
30 Sep 22 | 528 | -3,530 | 2,088 | 1,860 |
30 Jun 22 | 539 | -2,962 | 1,683 | 1,652 |
31 Mar 22 | 438 | -2,347 | 1,279 | 1,414 |
31 Dec 21 | 314 | -1,830 | 863 | 1,150 |
30 Sep 21 | 197 | -276 | 94 | 226 |
30 Jun 21 | 133 | -200 | 75 | 209 |
31 Mar 21 | 100 | -175 | 50 | 189 |
31 Dec 20 | 77 | -127 | 38 | 160 |
31 Dec 19 | 54 | -119 | 29 | 96 |
Quality Earnings: DNA is currently unprofitable.
Growing Profit Margin: DNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DNA is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare DNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNA is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-24.2%).
Return on Equity
High ROE: DNA has a negative Return on Equity (-86.48%), as it is currently unprofitable.